Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | SHBG | P04278 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.64 |
| ▸ | GUSB | P08236 | 1/20 | 0.64 |
| ▸ | G6PD | P11413 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | GPR183 | P32249 | 6/20 | 0.51 |
| ▸ | RORA | P35398 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.51 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.51 |
| ▸ | OSBP | P22059 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492219 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL602258 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14581228 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14613791 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL10301214 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL1952526 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL301939 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL14613826 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL2921296 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 | |
| SCHEMBL13753025 | 1.00 | CA1 (0.66) | CA1CA2CA9SHBGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300489-B1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HARBOR THERAPEUTICS INC (US) | 2015-11-11 | — | — | EP | claimed |
| US-20130066087-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 | Harbor Therapeutics, Inc. (US) | 2013-03-14 | — | — | US | claimed |
| US-8309746-B2 | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds | Harbor Therapeutics, Inc (US) | 2012-11-13 | — | — | US | claimed |
| US-20120214987-A1 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | BIOVIE INC. | 2012-08-23 | — | — | US | claimed |
| EP-2300489-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | Harbor BioSciences, Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| US-20090326251-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009149392-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | WO | claimed |
| US-20070066579-A1 | 5-androsten-3beta-ol steroid intermediates and processs for their preparation | WHITE MICHAEL J | 2007-03-22 | — | — | US | claimed |
| EP-1679317-A2 | 5-Androsten-3 -ol steroid intermediates and processes for fheir preparation | Pharmacia & Upjohn Company LLC (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050256095-A1 | Asthma and colitis treatment methods | BIOVIE INC. | 2005-11-17 | — | — | US | claimed |
| EP-1534732-A2 | 5 ANDROSTEN-3&bgr;-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | Pharmacia & Upjohn Company LLC (US) | 2005-06-01 | — | — | EP | claimed |
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | claimed |
| US-20040248861-A1 | Modified delta5-androstenes having improved bioavailability | KNELLER BRUCE W (US) | 2004-12-09 | — | — | US | claimed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| WO-2004016640-A2 | 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-26 | — | — | WO | claimed |
| US-20040034215-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | PHARMACIA & UPJOHN COMPANY | 2004-02-19 | — | — | US | claimed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | claimed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| US-11254924-B2 | Method for biocatalysis using filamentous fungi | THE UNIVERSITY OF THE WEST INDIES (JM) | 2022-02-22 | — | — | US | disclosed |
| US-20220002338-A1 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL | BIOVIE INC. | 2022-01-06 | — | — | US | disclosed |
| US-10995112-B2 | Crystalline solvate forms of a pharmaceutical | NEURMEDIX, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200190133-A1 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL | BIOVIE INC. | 2020-06-18 | — | — | US | disclosed |
| US-20180215778-A1 | METHOD FOR PREPARING SUBSTITUTED 3,7-DIHYDROXY STEROIDS | NEURMEDIX INC (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180208623-A1 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL | NEURMEDIX INC (US) | 2018-07-26 | — | — | US | disclosed |
| US-9994608-B2 | Method for preparing substituted 3,7-dihydroxy steroids | NEURMEDIX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180079775-A9 | METHOD FOR PREPARING SUBSTITUTED 3,7-DIHYDROXY STEROIDS | BIOVIE INC. | 2018-03-22 | — | — | US | disclosed |
| US-9877972-B2 | Treatment methods using pharmaceutical solid state forms | NEURMEDIX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9850271-B2 | Crystalline solvate forms of a pharmaceutical | NEURMEDIX, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9802976-B2 | — | — | 2017-10-31 | — | — | US | disclosed |
| US-20170152281-A1 | Crystalline solvate forms of a pharmaceutical | NEURMEDIX, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9555046-B2 | Crystalline anhydrate forms of a pharmaceutical | NEURMEDIX, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2093285-B1 | Method for biocatalysis using filamentous fungi | UNIV THE WEST INDIES (JM) | 2016-07-06 | — | — | EP | disclosed |
| US-20160175322-A9 | Treatment Methods Using Pharmaceutical Solid State Forms | Harbor Therapeutics, Inc. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160083415-A1 | Crystalline Anhydrate Forms Of A Pharmaceutical | Harbor Therapeutics, Inc. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160045516-A1 | Treatment Methods Using Pharmaceutical Solid State Forms | Harbor Therapeutics, Inc. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160039863-A1 | METHOD FOR PREPARING SUBSTITUTED 3,7-DIHYDROXY STEROIDS | NEURMEDIX INC (US) | 2016-02-11 | — | — | US | disclosed |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| EP-2273994-B1 | SOLID STATE FORMS OF A PHARMACEUTICAL | NEURMEDIX INC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2300489-B1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HARBOR THERAPEUTICS INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9163059-B2 | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds-2 | NEURMEDIX INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9115168-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-3 | NEURMEDIX, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9102702-B2 | Steroids having 7-oxygen and 17-heteroaryl substitution-2 | NEURMEDIX INC. (US) | 2015-08-11 | — | — | US | disclosed |
| EP-1807118-B1 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HARBOR BIOSCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | Harbor Therapeutics, Inc. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8586770-B2 | Unsaturated steroid compounds | Harbor Therapeutics, Inc. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8569275-B2 | Steroids having 7-oxgen and 17-heteroaryl substitution | Harbor Therapeutics, Inc. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130066087-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 | Harbor Therapeutics, Inc. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120302537-A1 | TREATMENT METHODS USING PHARMACEUTICAL SOLID STATE FORMS | Harbor Therapeutics, Inc. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120296105-A1 | CRYSTALLINE ANHYDRATE FORMS OF A PHARMACEUTICAL | Harbor Therapeutics, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8309746-B2 | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds | Harbor Therapeutics, Inc (US) | 2012-11-13 | — | — | US | disclosed |
| US-8252947-B2 | Solid state forms of a pharmaceutical | Harbor Therapeutics, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120214987-A1 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | BIOVIE INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| US-20110212935-A1 | COMPOSITIONS AND TREATMENT METHODS-4 | HARBOR BIOSCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110137057-A1 | Unsaturated Steroid Compounds | BIOVIE INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110129423-A1 | ANTICANCER COMPOUNDS AND SCREENING METHOD | BIOVIE INC. | 2011-06-02 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7935839-B2 | Sepsis treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2300489-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | Harbor BioSciences, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2298316-A1 | Therapeutic treatment methods | Harbor BioSciences, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298315-A1 | Therapeutic treatment methods | Harbor BioSciences, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7910571-B2 | 3 beta -hydroxy-16 alpha -fluoro-17 beta -aminoandrost-5-ene; immunostimulant, antiinflammatory agent; neutropenia, infections, blood cell deficiencies; interleukin, tumor necrosis factor, macrophage inflammatory protein, transforming growth factor, cyclooxygenase, and lipoxygenase inhibitor | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910755-B2 | Stem cell expansion and uses | HARBOR BIOSCIENCES, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2273994-A2 | SOLID STATE FORMS OF A PHARMACEUTICAL | Harbor BioSciences, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100227841-A1 | Patient populations and treatment methods | Harbor BioSciencs, Inc. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222315-A1 | Patient populations and treatment methods | Harbor BioSciencs, Inc. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010036822-A1 | PATIENT POPULATIONS AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100075937-A1 | Patient populations and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-7666842-B2 | Elastin peptide analogs and uses thereof | Connective Tissue Imagineering, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090326251-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2135611-A1 | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy | Hollis-Eden Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009149392-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090291933-A1 | SOLID STATE FORMS OF A PHARMACEUTICAL | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009124300-A2 | SOLID STATE FORMS OF A PHARMACEUTICAL | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090246850-A1 | METHOD FOR BIOCATALYSIS USING FILAMENTOUS FUNGI | UNIVERSITY OF THE WEST INDIES, A REGIONAL INSTITUTION, ESTABLISHED BY ROYAL CHARTER (JM) | 2009-10-01 | — | — | US | disclosed |
| EP-2093285-A1 | Method for biocatalysis using filamentous fungi | The University of the West Indies (JM) | 2009-08-26 | — | — | EP | disclosed |
| US-7547687-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7482334-B2 | Therapeutic treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1223941-B1 | THERAPEUTIC TREATMENTS FOR BLOOD CELL DEFICIENCIES USING SREROIDS | HOLLIS EDEN PHARMACEUTICALS (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080090791-A1 | Cystic fibrosis treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080085873-A1 | Disease treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20070275938-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275937-A1 | Therapeutic Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070265236-A1 | Asthma Treatment Methods | BIOVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070213309-A1 | Sepsis Treatment Methods | BIOVIE INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070203107-A1 | Pharmaceutical compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| EP-1539183-A4 | THERAPEUTIC TREATMENT METHODS | HOLLIS EDEN PHARMACEUTICALS (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-7196208-B2 | Processes for preparing 7-carboxy substituted steroids | PHARMACIA & UPJOHN COMPANY | 2007-03-27 | — | — | US | disclosed |
| US-20070066579-A1 | 5-androsten-3beta-ol steroid intermediates and processs for their preparation | WHITE MICHAEL J | 2007-03-22 | — | — | US | disclosed |
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1562974-B1 | PROCESSES FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1534732-B1 | 5 ANDROSTEN-3-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | PHARMACIA & UPJOHN CO LLC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1679317-A2 | 5-Androsten-3 -ol steroid intermediates and processes for fheir preparation | Pharmacia & Upjohn Company LLC (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060100185-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | WHITE MICHAEL J | 2006-05-11 | — | — | US | disclosed |
| US-20060088473-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060079492-A1 | Compositions and treatment methods | BIOVIE INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1644396-A1 | MICROBIAL PROCESS FOR THE PREPARATION OF 7-KETO DEHYDROEPIANDROSTERONE AND RELATED ANALOGS | Pharmacia & Upjohn Company LLC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060073099-A1 | Treatment screening methods | BIOVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1641811-A1 | MICROBIAL METHOD FOR HYDROLYSIS AND OXIDATION OF ANDROST-5-ENE AND PREGN-5-ENE STEROID ESTERS | Pharmacia & Upjohn Company LLC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20060040344-A1 | Microbial process for the preparation of 7-keto dehydroepiandrosterone and related analogs | WHITE MICHAEL J | 2006-02-23 | — | — | US | disclosed |
| US-7002028-B2 | 5-androsten-3β-ol steroid intermediates and processes for their preparation | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1562974-A1 | PROCESSES FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENES | Pharmacia & Upjohn Company LLC (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1539183-A1 | THERAPEUTIC TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534732-A2 | 5 ANDROSTEN-3&bgr;-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | Pharmacia & Upjohn Company LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050101581-A1 | Therapeutic treatment methods 2 | BIOVIE INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050059599-A1 | Elastin peptide analogs and uses thereof | CONNECTIVE TISSUE IMAGINEERING LLC. | 2005-03-17 | — | — | US | disclosed |
| US-20050054578-A1 | Elastin peptide analogs and uses thereof | SANDBERG LAWRENCE B (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005003148-A1 | MICROBIAL PROCESS FOR THE PREPARATION OF 7-KETO DEHYDROEPIANDROSTERONE AND RELATED ANALOGS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000865-A1 | MICROBIAL METHOD FOR HYDROLYSIS AND OXIDATION OF ANDROST-5-ENE AND PREGN-5-ENE STEROID ESTERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040265948-A1 | Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters | WHITE MICHAEL JON (US) | 2004-12-30 | — | — | US | disclosed |
| US-20040248861-A1 | Modified delta5-androstenes having improved bioavailability | KNELLER BRUCE W (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040220158-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | WHITE MICHAEL J (US) | 2004-11-04 | — | — | US | disclosed |
| US-20040171853-A1 | Using fungi; dihydroxylation; fusarium culture product | PHARMACIA & UPJOHN COMANY | 2004-09-02 | — | — | US | disclosed |
| WO-2004070048-A1 | A MICROBIAL PROCESS TO PREPARE 5-ANDROSTEN-3BETA, 7ALPHA, 15ALPHA-TRIOL-17-ONE AND RELATED ANALOGUES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
| US-6777389-B1 | INHIBITING CUTANEOUS EFFECTS OF AGING | CONNECTIVE TISSUE IMAGINEERING LLC | 2004-08-17 | — | — | US | disclosed |
| US-20040138187-A1 | Therapeutic treatment methods | BIOVIE INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004043986-A1 | PROCESSES FOR PREPARING C-7 SUBSTITUTED 5-ANDROSTENES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097475-A1 | Reacting steroid intermediate with nucleophilic reagent in presence of Lewis acid catalyst to produce 7-substituted steroid compound | PHARMACIA & UPJOHN COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-20040087562-A1 | Processes for preparing 7-carboxy substituted steroids | PHARMACIA & UPJOHN COMPANY | 2004-05-06 | — | — | US | disclosed |
| WO-2004019953-A1 | THERAPEUTIC TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004016640-A2 | 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20040034215-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | PHARMACIA & UPJOHN COMPANY | 2004-02-19 | — | — | US | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6620803-B2 | Cell proliferation; prevent apoptosis | VITASTEROL SARL (FR) | 2003-09-16 | — | — | US | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| US-20020165214-A1 | Cosmetic or dermatological use of 7-hydroxylated steroids | DRAY FERNAND (FR) | 2002-11-07 | — | — | US | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-0973524-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS | VITASTEROL S A R L (FR) | 2002-08-28 | — | — | EP | disclosed |
| EP-1223941-A2 | THERAPEUTIC TREATMENTS COMPRISING ADMINISTRATOIN OF CERTAIN STEROIDS FOR BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6407084-B2 | TOPICAL APPLICATION INTENDED TO PREVENT OR TREAT THE SYMPTOMS OF CUTANEOUS AGING AND/OR THE EFFECT OF ULTRAVIOLET RAYS ON THE SKIN, OF A 7-ALPHA OR 7-BETA SUBSTITUTED COMPOUND OF DEHYDROEPIANDROSTERONE OR PREGNENOLONE DERIVATIVES | VITASTEROL SARL (FR) | 2002-06-18 | — | — | US | disclosed |
| US-20010041696-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS | VITASTEROL SARL (FR) | 2001-11-15 | — | — | US | disclosed |
| WO-2001030802-A2 | THERAPEUTIC TREATMENTS COMPRISING ADMINISTRATION OF CERTAIN STEROIDS FOR BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| US-5804576-A | CANCER PREVENTIVE AGENTS, ANTI-OBESITY AGENTS, TREATMENT OF DIABETES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5714481-A | ADMINISTERING TO MAMMALIAN HOST A GLUCOSE-6-PHSOPHATE DEHYDROGENASE INHIBITOR, ANTICARCINOGENIC, ANTIOBASITY, ANTI-HYPERGLYCEMIC, ANTIAGING, ANTICHOLESTEROL AND ANTI-AUTOIMMUNE AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0133995-B1 | STEROIDS AND THERAPEUTIC COMPOSITIONS CONTAINING SAME | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| US-5028631-A | Anticancer, antiobesity, anticholesterol | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-07-02 | — | — | US | disclosed |
| EP-0423842-A2 | Steroids and therapeutic compositions containing same | Research Corporation (US) | 1991-04-24 | — | — | EP | disclosed |
| US-5001119-A | 16-substituted androstanes and 16-substituted androstenes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-03-19 | — | — | US | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
| EP-0133995-A2 | Steroids and therapeutic compositions containing same | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1985-03-13 | — | — | EP | disclosed |
| EP-0133995-A2 | Steroids and therapeutic compositions containing same | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1985-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275938-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | CA1 4653/4885CA2 4518/4885CA9 4374/4885 |
| US-20070275937-A1 | Therapeutic Treatment Methods | HSD3B1, HSD3B2, HSD17B1 | CA1 4653/4885CA2 4518/4885CA9 4374/4885 |
| US-20120296105-A1 | CRYSTALLINE ANHYDRATE FORMS OF A PHARMACEUTICAL | HSD3B1, HSD17B1, IL17A | CA1 31/4885CA2 90/4885CA9 121/4885 |
| US-10995112-B2 | Crystalline solvate forms of a pharmaceutical | IL17A, CYP27A1, HSD17B1 | CA1 1055/4885CA2 2567/4885CA9 3635/4885 |
| US-20090291933-A1 | SOLID STATE FORMS OF A PHARMACEUTICAL | IL17A, HSD3B1, HSD17B1 | CA1 111/4885CA2 210/4885CA9 324/4885 |
| US-20110212935-A1 | COMPOSITIONS AND TREATMENT METHODS-4 | HSD3B1, HSD3B2, HSD17B13 | CA1 4582/4885CA2 4635/4885CA9 4273/4885 |
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | CA1 3586/4885CA2 4100/4885CA9 4104/4885 |
| US-20120214987-A1 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS | CYP11B1, CYP11A1, HSD17B7 | CA1 1922/4885CA2 3847/4885CA9 2481/4885 |
| US-20060088473-A1 | Treatment screening methods | HSD3B1, HSD3B2, HSD17B11 | CA1 4395/4885CA2 4798/4885CA9 3912/4885 |
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | CA1 4009/4885CA2 4243/4885CA9 4274/4885 |
| US-20200190133-A1 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL | IL17A, CYP27A1, HSD17B1 | CA1 1055/4885CA2 2567/4885CA9 3635/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | CA1 2939/4885CA2 3932/4885CA9 3047/4885 |
| US-20070066579-A1 | 5-androsten-3beta-ol steroid intermediates and processs for their preparation | CYP17A1, NR5A1, HSD3B2 | CA1 3410/4885CA2 4638/4885CA9 3859/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | CA1 3803/4885CA2 3601/4885CA9 4049/4885 |
| US-20150353596-A1 | 17-Substituted Steroid Compounds | HSD3B1, HSD3B2, HSD17B13 | CA1 4794/4885CA2 4853/4885CA9 4658/4885 |
| US-20110129423-A1 | ANTICANCER COMPOUNDS AND SCREENING METHOD | CYP46A1, DHCR7, CYP27A1 | CA1 4005/4885CA2 4675/4885CA9 2623/4885 |
| US-20090326251-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS | HSD17B11, ESRRA, HSD17B7 | CA1 3733/4885CA2 4057/4885CA9 1787/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | CA1 3482/4885CA2 3704/4885CA9 3436/4885 |
| US-20060100185-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | CYP17A1, NR5A1, HSD3B2 | CA1 3364/4885CA2 4673/4885CA9 4012/4885 |
| US-20130066087-A1 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 | HSD17B11, ESRRA, ESRRB | CA1 3861/4885CA2 3327/4885CA9 2044/4885 |
| US-20180208623-A1 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL | IL17A, CYP27A1, HSD17B1 | CA1 1055/4885CA2 2567/4885CA9 3635/4885 |
| US-20160045516-A1 | Treatment Methods Using Pharmaceutical Solid State Forms | IL17A, HSD3B1, HSD17B1 | CA1 144/4885CA2 268/4885CA9 407/4885 |
| US-20160039863-A1 | METHOD FOR PREPARING SUBSTITUTED 3,7-DIHYDROXY STEROIDS | HSD17B7, ESRRA, HSD17B11 | CA1 4081/4885CA2 4063/4885CA9 2305/4885 |
| US-20170152281-A1 | Crystalline solvate forms of a pharmaceutical | HSD3B1, HSD17B1, IL17A | CA1 123/4885CA2 260/4885CA9 391/4885 |
| US-20060079492-A1 | Compositions and treatment methods | MPL, HPGDS, THPO | CA1 3435/4885CA2 4234/4885CA9 3344/4885 |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | CA1 4447/4885CA2 4813/4885CA9 4686/4885 |
| US-20020165214-A1 | Cosmetic or dermatological use of 7-hydroxylated steroids | SRD5A2, HSD3B1, NR1H3 | CA1 2946/4885CA2 2074/4885CA9 2302/4885 |
| US-20140018336-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-2 | HSD3B1, HSD3B2, HSD17B13 | CA1 4818/4885CA2 4722/4885CA9 4582/4885 |
| US-20050075321-A1 | Neurological disorder treatment methods | HSD17B1, HSD17B3, HSD3B1 | CA1 1832/4885CA2 3530/4885CA9 4573/4885 |
| US-20140018337-A1 | Steroids Having 7-Oxygen and 17-Heteroaryl Substitution-3 | HSD3B1, HSD3B2, HSD17B13 | CA1 4808/4885CA2 4753/4885CA9 4543/4885 |
| US-20080085873-A1 | Disease treatment methods | HSD3B1, HSD3B2, HSD17B1 | CA1 4542/4885CA2 4579/4885CA9 4137/4885 |
| US-20160175322-A9 | Treatment Methods Using Pharmaceutical Solid State Forms | IL17A, HSD3B1, HSD17B1 | CA1 144/4885CA2 268/4885CA9 407/4885 |
| US-20040034215-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | CYP17A1, NR5A1, HSD3B2 | CA1 3112/4885CA2 4632/4885CA9 3746/4885 |
| US-20070265236-A1 | Asthma Treatment Methods | HSD3B1, HSD3B2, HSD17B13 | CA1 4498/4885CA2 3938/4885CA9 4197/4885 |
| US-20040220158-A1 | 5-Androsten-3beta-ol steroid intermediates and processes for their preparation | CYP17A1, NR5A1, HSD3B2 | CA1 3112/4885CA2 4632/4885CA9 3746/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | CA1 4572/4885CA2 4774/4885CA9 4299/4885 |
| US-20060073099-A1 | Treatment screening methods | HSD17B11, HSD3B2, HSD3B1 | CA1 3804/4885CA2 4506/4885CA9 3707/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | CA1 3822/4885CA2 4597/4885CA9 3098/4885 |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | CA1 4572/4885CA2 4774/4885CA9 4299/4885 |
| US-20050101581-A1 | Therapeutic treatment methods 2 | HSD3B2, HSD3B1, HSD17B2 | CA1 4658/4885CA2 4338/4885CA9 4487/4885 |
| US-20040171853-A1 | Using fungi; dihydroxylation; fusarium culture product | ERG28, CYP17A1, CYP21A2 | CA1 2511/4885CA2 3095/4885CA9 1885/4885 |
| US-20050059599-A1 | Elastin peptide analogs and uses thereof | ELANE, CUTA, ENPEP | CA1 4538/4885CA2 4617/4885CA9 3703/4885 |
| US-20080090791-A1 | Cystic fibrosis treatment methods | HSD3B1, ELANE, CFTR | CA1 4825/4885CA2 4616/4885CA9 4273/4885 |
| US-20220002338-A1 | CRYSTALLINE SOLVATE FORMS OF A PHARMACEUTICAL | IL17A, CYP27A1, HSD17B1 | CA1 1055/4885CA2 2567/4885CA9 3635/4885 |
| US-20120302537-A1 | TREATMENT METHODS USING PHARMACEUTICAL SOLID STATE FORMS | IL17A, HSD3B1, HSD17B1 | CA1 144/4885CA2 268/4885CA9 407/4885 |
| US-20050054578-A1 | Elastin peptide analogs and uses thereof | ELANE, CUTA, ENPEP | CA1 4538/4885CA2 4617/4885CA9 3703/4885 |
| US-20050256095-A1 | Asthma and colitis treatment methods | HSD3B1, HSD17B1, HSD11B1 | CA1 2438/4885CA2 2263/4885CA9 3504/4885 |
| US-20160083415-A1 | Crystalline Anhydrate Forms Of A Pharmaceutical | HSD3B1, HSD17B1, IL17A | CA1 31/4885CA2 90/4885CA9 121/4885 |
| US-20040138187-A1 | Therapeutic treatment methods | ELANE, ALOX15, IL15 | CA1 4442/4885CA2 4417/4885CA9 4010/4885 |
| US-20010041696-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS | HSD17B7, CYP17A1, CYP21A2 | CA1 4842/4885CA2 4692/4885CA9 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.